

**Monthly information regarding the total number of voting rights and shares comprising the share capital**

Article L233-8-II of the Commercial Code  
Article 223-16 of the General Regulations of the AMF

**Paris, December 5<sup>th</sup>, 2023,**

Listing: Euronext Growth Paris  
ISIN code: FR0010609263, Ticker: ALMKT  
Website: [www.maunakeatech.com](http://www.maunakeatech.com)

Date	Number of shares comprising the capital in circulation	Total number of voting rights	
		Gross Total <sup>(1)</sup>	Net Total <sup>(2)</sup>
November 30 <sup>th</sup> , 2023	61,598,117	62,657,791	62,544,687

<sup>(1)</sup> The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.

<sup>(2)</sup> The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007.

\*\*\*

**About Mauna Kea Technologies**

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit [www.maunakeatech.com](http://www.maunakeatech.com).

**Mauna Kea Technologies - Investor Relations**

[investors@maunakeatech.com](mailto:investors@maunakeatech.com)

**NewCap - Investor Relations**

Aurélie Manavarere / Thomas Grojean

+33 (0)1 44 71 94 94

[maunakea@newcap.eu](mailto:maunakea@newcap.eu)